Solving Japan's Drug Lag: Why PM Takaichi Must Agree to a Fair U.S. Pricing Deal

With Japanese Prime Minister Sanae Takaichi meeting President Trump this week, we are re-airing our special episode from Tokyo. We explore why the U.S. delegation must prioritize a fair pricing agreement that ensures Japan pays its fair share while giving patients access to life-saving cures.As the US and Japan put renewed focus on their partnership in science and the life sciences, we are revisiting a special episode of the Making Medicine podcast recorded on the ground in Tokyo late last year to mark this critical geopolitical moment.This week's summit presents a rare win-win opportunity if the U.S. delegation focuses on securing a fair commercial pricing agreement. For years, arcane and arbitrary pricing schemes have limited the value Japan is willing to pay for medical breakthroughs. By pushing Japan to pay its "fair share" for innovation, U.S. leaders can help solve the severe drug lag that leaves 70 percent of new American medicines unavailable to Japanese patients. A modernized pricing agreement wouldn't just protect early-stage biopharma investments; it would give Japan's aging population access to the breakthroughs they desperately need.During this international panel, John Stanford sat down with a premier group of global investors to discuss the path forward. He was joined by Shaan Gandhi of Pfizer, Patrick Jordan of NovaQuest Capital Management, Heather Berger of Forge Life Sciences, and Johannes Freuhauf of Biolabs.The group explored how the Japanese government is systematically addressing structural challenges through unified agency alignment from the MHLW and METI. A major highlight of the conversation was a remarkably forward-looking program that offers a two-to-one non-dilutive matching grant for accredited international venture capital investments. The panel also discussed the rapid expansion of vital infrastructure, celebrating the announcement of a second Biolabs incubator facility opening in Tokyo in mid-2026.However, the investors agreed that early-stage funding must be paired with a predictable commercial pricing environment. To ensure sustainable global investment, Prime Minister Takaichi's administration must commit to valuing innovation across the entire value chain, allowing for the successful exits and capital recycling that fuel the next generation of medicines.Join the Conversation ⬇️What policy changes would most effectively help Japan reduce its drug lag?Do you believe government matching grants are the most effective way to accelerate early-stage biotech ecosystems?Can Japan build a globally competitive biotech sector without a modernized pricing agreement?Drop your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTime Stamps00:00 Episode disclaimer00:23 Japan episode introduction01:17 Why the US Japan meeting matters01:53 Japan’s drug lag problem02:47 Why Japan missed the COVID vaccine moment03:19 Live discussion from Tokyo06:36 Why BioLabs doubled down in Japan08:00 Japan’s science to startup opportunity14:00 Government alignment on biotech innovation20:23 Japan’s matching grant model25:46 Drug lag, pricing, and patient accessDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#japanbiotech #healthcarepolicy #drugdevelopment #lifesciences #medicalinnovation